Skip to main content
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALLO ISIN · US0197701065 US Manufacturing
Open in API
Filings indexed 523 across all filing types
Latest filing 2026-05-28 Proxy Solicitation & In…
Country US United States of America
Listing US ALLO

About Allogene Therapeutics, Inc.

https://allogene.com/

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement
2026-05-28 English
8-K
Board/Management Information Classification · 85% confidence The document is a Form 8-K current report filed under Item 5.02, detailing the departure of the CEO, appointment of a new President and CEO, changes to the Board, and related executive compensation arrangements. This is clearly an announcement of changes in senior management and board composition, fitting the Board/Management Information category.
2026-05-28 English
DEFA14A
Proxy Solicitation & Information Statement
2026-05-20 English
8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)
Regulatory Filings
2026-05-13 English
424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus supplement and accompanying prospectus for a public offering of common stock by Allogene Therapeutics, Inc. It includes information about the offering size, price, underwriting details, risk factors, company overview, recent developments, and clinical trial data. The document is filed pursuant to Rule 424(b)(5), which is a SEC rule related to prospectus supplements for securities offerings. The content focuses on capital raising through a stock offering, including underwriting and use of proceeds, rather than financial results, management changes, or regulatory certifications. This matches the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length is substantial and contains detailed offering terms, not just an announcement or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP with high confidence.
2026-04-15 English
424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement and accompanying prospectus for a public offering of common stock by Allogene Therapeutics, Inc. It includes detailed information about the offering, risk factors, use of proceeds, underwriting, and company overview. The document is filed pursuant to SEC Rule 424(b)(5), which relates to prospectus supplements for securities offerings. The content focuses on capital raising through a stock offering, including underwriting details and market information. There is no financial statement data, audit information, management discussion, or other report types present. This document fits the definition of a Capital/Financing Update (CAP), as it provides updates on company fundraising and capital structure changes through a public offering of shares.
2026-04-13 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.